[go: up one dir, main page]

DK1966151T3 - Polycykliske indazolderivater, der er ERK-hæmmere - Google Patents

Polycykliske indazolderivater, der er ERK-hæmmere

Info

Publication number
DK1966151T3
DK1966151T3 DK06845064.2T DK06845064T DK1966151T3 DK 1966151 T3 DK1966151 T3 DK 1966151T3 DK 06845064 T DK06845064 T DK 06845064T DK 1966151 T3 DK1966151 T3 DK 1966151T3
Authority
DK
Denmark
Prior art keywords
indazole derivatives
erk inhibitors
polycyclic
polycyclic indazole
erk
Prior art date
Application number
DK06845064.2T
Other languages
English (en)
Inventor
Hugh Zhu
Robert Sun
Yiji Wu
Azim A Celebi
Alan Cooper
Yongqi Deng
Gerald W Shipps Jr
Neng-Yang Shih
Joseph Kelly
Ronald Doll
Yang Nan
Tong Wang
Jagdish Desai
James Wang
Youhao Dong
Vincent S Madison
Alan Hruza
M Arshad Siddiqui
Ahmed Samatar
Sunil Paliwal
Hon-Chung Tsui
Sobhana Babu Boga
Li Xiao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1966151T3 publication Critical patent/DK1966151T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK06845064.2T 2005-12-13 2006-12-11 Polycykliske indazolderivater, der er ERK-hæmmere DK1966151T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74985605P 2005-12-13 2005-12-13
PCT/US2006/046959 WO2007070398A1 (en) 2005-12-13 2006-12-11 Polycyclic indazole derivatives that are erk inhibitors

Publications (1)

Publication Number Publication Date
DK1966151T3 true DK1966151T3 (da) 2012-01-30

Family

ID=37969564

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06845064.2T DK1966151T3 (da) 2005-12-13 2006-12-11 Polycykliske indazolderivater, der er ERK-hæmmere

Country Status (28)

Country Link
US (1) US20070191604A1 (da)
EP (1) EP1966151B1 (da)
JP (1) JP4881957B2 (da)
KR (1) KR101417136B1 (da)
CN (1) CN101370784B (da)
AR (1) AR056891A1 (da)
AT (1) ATE527240T1 (da)
AU (1) AU2006326616B2 (da)
BR (1) BRPI0619823B8 (da)
CA (1) CA2633023C (da)
CY (1) CY1112760T1 (da)
DK (1) DK1966151T3 (da)
EC (1) ECSP088550A (da)
ES (1) ES2372976T3 (da)
HR (1) HRP20110892T1 (da)
IL (1) IL192034A (da)
MY (1) MY149430A (da)
NO (1) NO341831B1 (da)
NZ (1) NZ569087A (da)
PE (2) PE20071095A1 (da)
PL (1) PL1966151T3 (da)
PT (1) PT1966151E (da)
RS (1) RS51981B (da)
RU (1) RU2442778C9 (da)
SI (1) SI1966151T1 (da)
TW (1) TWI344466B (da)
WO (1) WO2007070398A1 (da)
ZA (1) ZA200805525B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ES2353437T3 (es) * 2006-02-16 2011-03-02 Schering Corporation Derivados de pirrolidina como inhibidores de erk.
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
PE20090326A1 (es) * 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
EP2220503A1 (en) * 2007-11-30 2010-08-25 Schering Corporation Braf biomarkers
SG188179A1 (en) * 2008-02-21 2013-03-28 Merck Sharp & Dohme Compounds that are erk inhibitors
WO2009111279A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine raf inhibitors
US8637554B2 (en) * 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer
US8586543B2 (en) * 2008-08-19 2013-11-19 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011002887A1 (en) 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
MY174452A (en) 2009-10-14 2020-04-19 Schering Corp Substituted piperidines that increase p53 activity and the uses thereof
WO2011123937A1 (en) * 2010-04-06 2011-10-13 University Health Network Kinase inhibitors and method of treating cancer with same
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012015932A2 (en) * 2010-07-27 2012-02-02 Protexer, Inc. Shoe cover removal apparatus
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CA2830780A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
CA2833009A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
US8901142B2 (en) 2011-07-26 2014-12-02 Merck Sharp & Dohme Corp. Fused tricyclic compounds as mTOR inhibitors
WO2013062923A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
ITMI20120135A1 (it) * 2012-02-02 2013-08-03 Diab Int Ab Procedimento per la produzione di schiume di pet e schiume di pet ottenute con questo procedimento
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN103450163B (zh) * 2012-05-29 2017-06-23 中国医学科学院药物研究所 吲唑类化合物、其制备方法及其药物用途
JP6186440B2 (ja) 2012-09-19 2017-08-23 ノバルティス アーゲー キナーゼ阻害剤としてのジヒドロピロリジノピリミジン
JP6280554B2 (ja) * 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Erk阻害剤である新規化合物
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
KR101910720B1 (ko) 2013-11-01 2018-10-22 노파르티스 아게 키나제 억제제로서의 아미노헤테로아릴 벤즈아미드
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
EP3355923B1 (en) 2015-10-01 2022-02-23 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
CA3017567A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
BR112019005305A2 (pt) * 2016-10-05 2019-07-02 Zeno Royalties & Milestones Llc compostos espirocíclicos
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶2介導的傳訊之抑制劑
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
CZ20013540A3 (cs) * 2000-02-05 2002-03-13 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
AU2003278249B8 (en) * 2002-09-05 2010-11-18 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same

Also Published As

Publication number Publication date
WO2007070398A1 (en) 2007-06-21
ZA200805525B (en) 2009-11-25
CN101370784A (zh) 2009-02-18
AU2006326616B2 (en) 2012-09-06
ECSP088550A (es) 2008-07-30
PE20100562A1 (es) 2010-08-20
NZ569087A (en) 2011-09-30
NO20083114L (no) 2008-09-12
EP1966151B1 (en) 2011-10-05
KR20080085018A (ko) 2008-09-22
AU2006326616A1 (en) 2007-06-21
CY1112760T1 (el) 2016-02-10
PT1966151E (pt) 2011-12-20
RS51981B (sr) 2012-02-29
ATE527240T1 (de) 2011-10-15
ES2372976T3 (es) 2012-01-30
CA2633023C (en) 2015-11-24
PE20071095A1 (es) 2007-11-19
MY149430A (en) 2013-08-30
EP1966151A1 (en) 2008-09-10
NO341831B1 (no) 2018-01-29
IL192034A (en) 2014-08-31
JP2009519338A (ja) 2009-05-14
BRPI0619823B8 (pt) 2021-05-25
RU2442778C2 (ru) 2012-02-20
AR056891A1 (es) 2007-10-31
RU2442778C9 (ru) 2012-08-10
HRP20110892T1 (hr) 2011-12-31
BRPI0619823A2 (pt) 2011-11-08
CA2633023A1 (en) 2007-06-21
US20070191604A1 (en) 2007-08-16
TWI344466B (en) 2011-07-01
PL1966151T3 (pl) 2012-02-29
BRPI0619823A8 (pt) 2019-01-22
HK1114851A1 (en) 2008-11-14
RU2008128119A (ru) 2010-01-20
BRPI0619823B1 (pt) 2020-11-17
CN101370784B (zh) 2012-10-10
TW200732324A (en) 2007-09-01
JP4881957B2 (ja) 2012-02-22
IL192034A0 (en) 2008-12-29
KR101417136B1 (ko) 2014-08-07
SI1966151T1 (sl) 2012-02-29

Similar Documents

Publication Publication Date Title
DK1966151T3 (da) Polycykliske indazolderivater, der er ERK-hæmmere
CY2021013I2 (el) Δι-αρυλ μετα-πυριμιδινο αναστολεις κινασων
DK2078010T3 (da) Polycyklisk heteroaryl-substituerede triazoler, der er anvendelige som axl-hæmmere
DK1979356T3 (da) Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
LTC1907382I2 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
HRP20150012T1 (xx) 39-dezmetoksi derivati rapamicina
DE602006011363D1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
DK1934236T3 (da) Heterobifunktionelle pan-selektininhibitorer
ATE517886T1 (de) Pyrazolderivate
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
ATE440837T1 (de) Indazol-heteroaryl-derivate
ATE493403T1 (de) Kinaseinhibitoren
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
DK1711177T3 (da) 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
PL1971588T3 (pl) Pochodne tiglien-3-onu
FI20065358L (fi) Järjestely puunkorjuuseen
ATE418545T1 (de) Nnrt-inhibitoren
ITRE20050027U1 (it) Spaccalegna perfezionato
ITRE20050028U1 (it) Spaccalegna perfezionato